Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Common Equity (2021 - 2026)

Zentalis Pharmaceuticals has reported Common Equity over the past 6 years, most recently at $182.7 million for Q1 2026.

  • For Q1 2026, Common Equity fell 38.15% year-over-year to $182.7 million; the TTM value through Mar 2026 reached $182.7 million, down 38.15%, while the annual FY2025 figure was $216.2 million, 35.88% down from the prior year.
  • Common Equity for Q1 2026 was $182.7 million at Zentalis Pharmaceuticals, down from $216.2 million in the prior quarter.
  • Over five years, Common Equity peaked at $523.3 million in Q2 2023 and troughed at $182.7 million in Q1 2026.
  • A 5-year average of $366.7 million and a median of $382.6 million in 2024 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: increased 22.18% in 2023 and later tumbled 38.15% in 2026.
  • Year by year, Common Equity stood at $434.0 million in 2022, then rose by 0.75% to $437.3 million in 2023, then dropped by 22.89% to $337.2 million in 2024, then tumbled by 35.88% to $216.2 million in 2025, then decreased by 15.51% to $182.7 million in 2026.
  • Business Quant data shows Common Equity for ZNTL at $182.7 million in Q1 2026, $216.2 million in Q4 2025, and $252.9 million in Q3 2025.